The early use of radionuclides in the UK was hindered by the McMahon Act in the US prohibiting the export of radioisotopes made in reactors until 1947. However as one of the peaceful uses of atomic energy UK government money was being poured into the Atomic Energy Research Establishment at Harwell to produce radioisotopes. Already in 1947 J S Mitchell listed most of the radioisotopes that would be used as tracers. The fi rst isotope conference sponsored by Harwell was held in Oxford in 1951 Fig. 2.2 [ 1 ] . By 1954 colloidal gold bismuth 206 and phosphorus were being produced for therapy and iodine 131 iron 59 chromium 51 for human diagnostic procedures. With the support of the Medical Research Council medical radioisotope units managed by physicists were being formed. At the Hammersmith Hospital the fi rst therapeutic dose of P-32 was used in November 1947 to treat a young girl with a glioma [ 1 , 2 ] . By 1954 Professor Sir David Smithers at the Royal Cancer Hospital London listed treatments on 96 patients using 32 P, 131 I, 24 Na, 82 Br, and 198 Au [ 3 ] . The non-therapeutic use of radioisotopes concentrated primarily on human physiology. In 1957 John West studied lung perfusion with oxygen-15 produced by the fi rst recently installed cyclotron at the MRC unit at the Hammersmith Hospital. Other in vitro studies included those on whole body water, blood volume and red cell turnover, calcium metabolism, cardiac and renal function.
The original reference book was that of Veall and Vetter 1958 entitled Radioisotopes in Clinical Research and Diagnosis (later edited by Belcher and Vetter). Counting was done using home-made circuitry with Geiger Counters. Norman Veall devised a circular array of Geiger counters to count urine in a Winchester bottle. These were eventually replaced by scalers and ratemeters made by E K Cole in Southend and Isotope Developments Ltd Aldermaston which later became part of Nuclear Enterprises Edinburgh. Norman Veall is remembered by the Norman Veall medal presented to a clinical scientist annually at the BNMS.
A key development of in vitro studies in the UK was made by Roger Ekins at the Middlesex Hospital London who in 1960 enabled the quantitative determination of thyroid hormones in blood samples using radioactive isotopes and specifi c binding proteins [ 4 ] . Radioactive B 12 was produced by J M Bradley at the Hammersmith Hospital with high specifi c activity cobalt-56 with the help of Glaxo. Direct evidence of B 12 absorption in the ileum in 1959 by found by Booth and Mollin who studied the distribution of radioactivity in the intestine after oral administration of radio labelled B 12. using a Geiger counter during a laparotomy [ 5 ] .
In 1949 Ansell and Rotblat in Liverpool made the fi rst radioisotope image in the UK of a patient with a retrosternal goiter [ 6 ] . By 1955 the precursor of imaging used hand held Geiger counters to plot iso-contours of iodine 131 activity in the thyroid gland. Russell Herbert also in Liverpool used a small calcium half inch diameter tungstate crystal on an early photo multiplier tube to improve the sensitivity. Early single and multibore lead collimators improved the resolution.
An early scintillation detector designed for brain studies with Iodine 131 fl uorescein was made in March 1951 by Belcher and Evans at the Royal Cancer Hospital (now the Royal Marsden Hospital) in London. The photomultiplier tube had to be cooled by liquid nitrogen to reduce the background noise. To avoid the possibility of frostbite, the patient's skin and the crystal were separated by a long Perspex light guide! Also in 1951 rectilinear scanning was being developed to make iodine 131 thyroid imaging easier. The fi rst device in the UK was made at the Royal Cancer Hospital London in 1951 to image initially radionuclide sources and then the thyroid gland. The Mayneord scanner displayed images on a Cathode Ray Tube, used Geiger counters, collimator, background subtraction and a clever raster scanning mechanism ( Fig. 2.3 ) . The scanner was preceded in 1950 by that shown by Ziedes des Plantes at the London International Radiological Congress [ 7 ] . Benedict Cassen in the US also published his paper on a thyroid scanner in Nucleonics 1951.
Professor Val Mayneord inventor of the fi rst UK radioisotope scanner and his wife Audrey met with Professor Ian Donald inventor of the ultrasound scanning in the Nuclear Medicine and Ultrasound Department at the Royal Marsden Hospital in Sutton Fig. 2.4 .
The fi rst home made whole body scanner with a colour print out was built in 1957 at the Hammersmith Hospital by Mallard and Peachey [ 8 ] . Also home-made was the fi rst UK digital whole body SPECT scanner in Aberdeen. The fi rst commercial Tri-D scanner was installed in the Royal Marsden Hospital Sutton in 1963. It lacked adequate collimation and soon after a 3″ Picker rectilinear scanner was purchased. In the days before ultrasound I-131 labeled albumin was used to In the mid 1960s Glass and Westerman installed the UK's fi rst Anger Gamma Camera at the Hammersmith.
A local fi rm Ekco Electronics Ltd in Southend constructed an Anger type gamma camera in 1964 using 9 photomultipler tubes and a 5 in. cryatal. It was not a great commercial success.
In 1977 another local fi rm J&P constructed the fi rst UK tomoscanner with the assistance of David Keeling and Andrew Todd-Pokropek. It was placed in the Middlesex Hospital London for evaluation. Tl 201 scans using it were published in 1979 from the UK and France.
In the early days of renography Marcus Hall a radiotherapist at Canterbury Hospital developed a technique to eliminate blood background activity [ 9 ] . A computerized version of this technique was later developed by Britton and Brown in 1970.
1967 was a good year for innovation. The fi rst paper using F-18 produced by the MRC cyclotron unit for rectilinear scans of bone showed a massive improvement in sensitivity from strontium-89 was published in 1967. With a half life of 109.8 min it was fortunate that the traffi c fl ow and the number of traffi c lights between Hammermith and Royal Marsden in Sutton was quite low [ 10 ] . In the same year Norman Veall published with Steve Garnett the still used technique for the measurement of Glomerular Filtration Rate [ 11 ] . Initially devised to improve tumour detection in brain scanning a ratio subtract device was constructed in the physics workshop in the Institute of Cancer Research in Sutton Surrey in 1967 [ 12 ] . Later the device was used to eliminate the liver uptake of seleno-methionine in pancreas scanning [ 13 ] . The same technique was performed on an early digital computer by Intertechnique Fig. 2.6 . It is interesting to refl ect on how exciting such awful images were. In fact this was a good example since many pancreas images consisted of about 15 dots.
In 1969 Roy Parker with his colleagues from the Atomic Weapons Research Establishment developed the fi rst semiconductor camera [ 14 ] . Using a cooled germanium detector clear images of a rat's tiny thyroid were shown at an IAEA Medical Radioisotope Scintigraphy meeting in Vienna long before the invention of the current solid state cameras. Kromek in the UK is currently advancing CZT technology to provide similar high resolution solid state SPECT camera imaging without the need for cooling.
Fazio Tc based ventilation: perfusion imaging was the second most frequent imaging procedure in the UK after 99m Tc bone scanning. As the krypton generator was delivered to the individual hospitals only once or twice per week it was important for patients to have their suspected pulmonary FDG Lung cancer PET imaging was the fi rst procedure to be reimbursed in the USA. Also the enhanced uptake of 18 FDG in breast cancer was reported by Beaney at that time. It should also be noted that the fi rst use of FDG was in the UK by Bessel et al. who explored its use as an anti-cancer agent [ 18 ] The introduction of Sr-89 by Amersham International (Metastron) led to a study of a treatment for painful bone metastases from prostate cancer by the Southampton Group in 1991. A randomized trial of 32 patients showed the benefi t of the treatment against stable strontium [ 19 ] . In 2002 a grant from the National Institutes of Health enabled the Royal Marsden/Institute of Cancer Research group to test the feasibility and toxicity of high activities of Rhenium-186 hydroxyethylidene diphosphonate, with peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone [ 20 ] . It was hoped that the high activities would ablate the metastases as well as relieving bone pain. The long term results of that study are being evaluated.
More recently in 2013 the Royal Marsden published a multicentre Phase 3 study on the use of Re-223 for the palliation of bone pain on the effect on overall survival from metastases from castration resistant prostate cancer. The result showed a signifi cant improvement on overall survival [ 21 ] .
The fi rst administration of radioiodine for thyroid cancer in the UK was given by Sir Eric Pochin in 1949. While the results from the use of radioiodine thyroid cancer have been excellent as early as 1964 Pochin was already recording untoward side effects from its use. There remains controversy on the balance between giving high activities to ensure total eradication of any residual disease and giving low activities to minimize the risks and shorten isolation in the hospital.
A fi rst UK wide randomised HiLo study compared the effectiveness of 30 and 90 mCi of I-131 for post operative ablation of residual thyroid tissue. In the paper published in the New England Journal of Medicine in 2012 the results of the HiLo study opened the possibility of a complete change in practice reducing the post operative ablative administered activity [ 22 ] . Following the success of that trial a new UK nation-wide study comparing the administration of Iodine 131 with none in low risk patients is being carried out.
The UK can be proud of its long record of the development of radionuclide studies. Its input has ranged from the introduction of new radionuclides and techniques, the development of new equipment, and the use of radionuclides in a wide variety of diseases. It is fortunate that the innovation and research continues with the development at Kings of Ga-68 compounds which should widen the use of high resolution PET imaging both in the number of applications and its spread to centres distant from the cyclotrons. 
